William P. Quinn bought $2,835 of BOLT
President, CEO and CFO at Bolt Biotherapeutics, Inc.. 5,000 shares at an average of $0.57, traded Jun 6, 2024, filed May 5, 2025.
Score components
- +25RoleCEO
- 0Trade size$3k at market
- +3Relative to holdingsHoldings up 14%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.4%, 3m -18.8%, 6m -19.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-063840, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 16, 2024 | POpen-market purchase Common Stock | +2,500 | $0.50 | $1,241 | 41,272 | May 5, 2025 |
| Jun 6, 2024 | POpen-market purchase Common Stock | +2,500 | $0.64 | $1,594 | 38,772 | May 5, 2025 |
| May 1, 2025 | AGrant or award Stock Option (Right to Buy)derivative | +700,000 | $0.00 | $0 | 700,000 | May 5, 2025 |
Related signals
Other insiders at Bolt Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | Bolt Biotherapeutics, Inc. | William P. Quinn President, CEO and CFO | $2,469 637 shares | +28% | |
| 57Moderate | Bolt Biotherapeutics, Inc. | William P. Quinn President, CEO and CFO | $58k 17,566 shares | -41% | |
| 29Weak | Bolt Biotherapeutics, Inc. | Sarah Nemec Senior VP, Finance and PAO | $1,973 509 shares | +36% | |
| 45Moderate | Bolt Biotherapeutics, Inc. | Sarah Nemec Senior VP, Finance and PAO | $26k 7,842 shares | -31% | |
| 51Moderate | Bolt Biotherapeutics, Inc. | Grant Yonehiro Chief Operating Officer | $44k 13,176 shares | -43% | |
| 34Weak | Bolt Biotherapeutics, Inc. | Sarah Nemec Senior VP, Finance and PAO | $576 125 shares | +10% | |
| 44Moderate | Bolt Biotherapeutics, Inc. | William P. Quinn President, CEO and CFO | $576 125 shares | +6% | |
| 44Moderate | Bolt Biotherapeutics, Inc. | William P. Quinn President, CEO and CFO | $687 125 shares | +6% | |
| 34Weak | Bolt Biotherapeutics, Inc. | Sarah Nemec Senior VP, Finance and PAO | $687 125 shares | +15% | |
| 29Weak | Bolt Biotherapeutics, Inc. | Sarah Nemec Senior VP, Finance and PAO | $2,835 5,000 shares | +44% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.